Emerald Mutual Fund Advisers Trust Cogent Biosciences, Inc. Transaction History
Emerald Mutual Fund Advisers Trust
- $1.47 Billion
- Q2 2025
A detailed history of Emerald Mutual Fund Advisers Trust transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Emerald Mutual Fund Advisers Trust holds 895,412 shares of COGT stock, worth $10.3 Million. This represents 0.44% of its overall portfolio holdings.
Number of Shares
895,412Holding current value
$10.3 Million% of portfolio
0.44%Shares
1 transactions
Others Institutions Holding COGT
# of Institutions
203Shares Held
117MCall Options Held
2.84MPut Options Held
828K-
Paradigm Biocapital Advisors LP New York, NY10.4MShares$120 Million3.47% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.49MShares$98.1 Million7.28% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$84.2 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.96MShares$80.4 Million10.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.52MShares$75.3 Million0.0% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $760M
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...